EP1326605A4 - Procedes servant a inhiber la proliferation et a induire l'apoptose dans des cellules cancereuses - Google Patents

Procedes servant a inhiber la proliferation et a induire l'apoptose dans des cellules cancereuses

Info

Publication number
EP1326605A4
EP1326605A4 EP01935770A EP01935770A EP1326605A4 EP 1326605 A4 EP1326605 A4 EP 1326605A4 EP 01935770 A EP01935770 A EP 01935770A EP 01935770 A EP01935770 A EP 01935770A EP 1326605 A4 EP1326605 A4 EP 1326605A4
Authority
EP
European Patent Office
Prior art keywords
methods
cancer cells
inducing apoptosis
inhibiting proliferation
proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01935770A
Other languages
German (de)
English (en)
Other versions
EP1326605A1 (fr
Inventor
Thomas E Adrian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creighton University
Original Assignee
Creighton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creighton University filed Critical Creighton University
Publication of EP1326605A1 publication Critical patent/EP1326605A1/fr
Publication of EP1326605A4 publication Critical patent/EP1326605A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01935770A 2000-05-09 2001-05-08 Procedes servant a inhiber la proliferation et a induire l'apoptose dans des cellules cancereuses Withdrawn EP1326605A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21934400P 2000-05-09 2000-05-09
US219344P 2000-05-09
PCT/US2001/040697 WO2001085166A1 (fr) 2000-05-09 2001-05-08 Procedes servant a inhiber la proliferation et a induire l'apoptose dans des cellules cancereuses

Publications (2)

Publication Number Publication Date
EP1326605A1 EP1326605A1 (fr) 2003-07-16
EP1326605A4 true EP1326605A4 (fr) 2004-03-17

Family

ID=22818912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01935770A Withdrawn EP1326605A4 (fr) 2000-05-09 2001-05-08 Procedes servant a inhiber la proliferation et a induire l'apoptose dans des cellules cancereuses

Country Status (11)

Country Link
EP (1) EP1326605A4 (fr)
JP (1) JP2003532675A (fr)
KR (1) KR20030019372A (fr)
CN (1) CN1237968C (fr)
AU (1) AU2001261832A1 (fr)
BR (1) BR0110473A (fr)
CA (1) CA2408622A1 (fr)
MX (1) MXPA02010974A (fr)
NO (1) NO20025343L (fr)
NZ (1) NZ522387A (fr)
WO (1) WO2001085166A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
EP2034022A1 (fr) * 2007-09-10 2009-03-11 Universite Libre De Bruxelles Récepteur de la lipocaline soluble liant le leukotriène B4 issu de Ixodes ricinus
US9187411B2 (en) 2012-01-10 2015-11-17 Eli Lilly And Company Leukotriene B4 antagonist compound
WO2014175253A1 (fr) 2013-04-22 2014-10-30 株式会社栃木臨床病理研究所 Agent antitumoral
MY180165A (en) 2013-12-20 2020-11-24 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
WO1996006604A2 (fr) * 1994-08-31 1996-03-07 Eli Lilly And Company Procedes d'identification et de traitement de tumeurs resistantes
WO2001034137A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques destinees au traitement du cancer
WO2001034135A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques pour traitement des cancers
WO2001034198A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques pour traitement des cancers
WO2001034197A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques aux fins du traitement de cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910505A (en) * 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
WO1996006604A2 (fr) * 1994-08-31 1996-03-07 Eli Lilly And Company Procedes d'identification et de traitement de tumeurs resistantes
WO2001034137A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques destinees au traitement du cancer
WO2001034135A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques pour traitement des cancers
WO2001034198A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques pour traitement des cancers
WO2001034197A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques aux fins du traitement de cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO0185166A1 *
STEELE V E ET AL: "LIPOXYGENASE INHIBITORS AS POTENTIAL CANCER CHEMOPREVENTIVES", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, AMERICAN ASSOCIATION FOR CANCER RESEARCH,, US, vol. 8, no. 5, May 1999 (1999-05-01), pages 467 - 483, XP000984604, ISSN: 1055-9965 *

Also Published As

Publication number Publication date
CA2408622A1 (fr) 2001-11-15
WO2001085166A1 (fr) 2001-11-15
CN1237968C (zh) 2006-01-25
CN1429111A (zh) 2003-07-09
NO20025343D0 (no) 2002-11-07
BR0110473A (pt) 2003-04-01
NZ522387A (en) 2003-09-26
MXPA02010974A (es) 2004-09-06
EP1326605A1 (fr) 2003-07-16
NO20025343L (no) 2003-01-09
JP2003532675A (ja) 2003-11-05
KR20030019372A (ko) 2003-03-06
AU2001261832A1 (en) 2001-11-20

Similar Documents

Publication Publication Date Title
AU2003284242A8 (en) Methods and compositions for use in treating cancer
AU2002252160A1 (en) Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation
MXPA02001866A (es) Cateter de drenaje lumbar.
AU3104102A (en) Local regional chemotherapy and radiotherapy using in situ hydrogel
HK1045299B (zh) 細胞增殖抑制劑
AU2003243373A8 (en) Cell migration inhibiting compositions and methods and compositions for treating cancer
AU3731400A (en) Methods and compositions useful in inhibiting apoptosis
EP1587476A4 (fr) Compositions et procedes pour la cancerotherapie
AU2003258061A8 (en) Therapeutic inhibitionof protein kinases in cancer cells
AU5137901A (en) Method to inhibit lipoxygenase and cancer cell proliferation
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
EP1499597A4 (fr) Composes et methodes permettant d'induire l'apoptose chez des cellules de proliferation
AU2002356898A8 (en) Gene amplification and overexpression in cancer
EP1664739A4 (fr) Systeme de traitement en ligne et d'irradiation
EP1609802A4 (fr) Facteur transcriptionnel induisant l'apoptose dans une cellule cancereuse
EP1501855A4 (fr) Nouvelles compositions et nouveaux procedes pour le cancer
EP1326605A4 (fr) Procedes servant a inhiber la proliferation et a induire l'apoptose dans des cellules cancereuses
HK1048599A1 (zh) 癌細胞植入抑制劑
GB2389788B (en) Methods for inducing apoptosis and inhibiting proliferation in cancer cells
EP1636384A4 (fr) Amplification et surexpression geniques dans le cancer
GB9818712D0 (en) In pond multi-skimmer
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
EP1583501A4 (fr) Nouvelles compositions et procedes utilises dans le cadre du cancer
GB2419530B (en) Human prostate cell lines in cancer treatment
GB0111211D0 (en) Water storage and distribution apparatus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021205

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040130

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/00 B

Ipc: 7A 61K 31/445 B

Ipc: 7A 61K 31/44 B

Ipc: 7A 61K 31/352 B

Ipc: 7A 61K 31/194 B

Ipc: 7A 61K 31/41 A

17Q First examination report despatched

Effective date: 20041007

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061031

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1057471

Country of ref document: HK